Roche’s Pirfenidone Bet Validates China Venture
This article was originally published in PharmAsia News
Executive Summary
China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.